Janssen Pharmaceutica Nv

Other

Janssen Biotech, Inc.

Carl L Manthey

Carl R Illig

Mark James Wall

Sanath K Meegalla

Jinsheng Chen

Christopher J Molloy

Christopher M Flores

Shelley K Ballentine

Kenneth J Wilson

M Jonathan Rudolph

Renee Louise Desjarlais

Renee L DesJarlais

Aihua Wang

Kristi A Leonard

Roger Francis Bone

Anne Fourie

Kenneth Jerome Wilson

Brett A Tounge

Joseph Kent Barbay

Barry A Springer

Kenneth Rhodes

Cynthia M Milligan

Frank A Lewandowski

Lawrence C Kuo

Hong Mimi Zhou

Robert Scannevin

Richard Scott Alexander

Matthew J Todd

John Curtis Spurlino

Paul F Jackson

Diane M Maguire

Celine Schalk-Hihi

John A Manthey

Ingrid Christa Deckman

Paul H Kim

Jonathan Rudolph

Antonio Montanari

Carl Crysler

Ryan Eberwine

Beverley Moore

Shelley K Balltentine

Ken Wilson

Jingsheng Chen

Anti-HLA-C6 antibodies and antigen-binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, methods of producing the antibodies, and methods of using the antibodies for treating or preventing diseases, such as autoimmune diseases.

Anti-HLA-C antibodies and uses thereof

The present invention includes a crystal comprising a complex of the pro form of a matrix metalloprotease (proMMP) and a small-molecule allosteric processing inhibitor that inhibits that activation of the proMMP, methods for identifying small-molecule allosteric processing inhibitors that inhibit the activation of a proMMP, and methods of treatment using small-molecule allosteric processing inhibitors that inhibit the activation of a proMMP. The present invention relates to the crystal structure of a complex of proMMP9 bound to a small-molecule allosteric processing inhibitor that inhibits activation of proMMP9. The invention further relates to the use of the methods and the crystal and related structural information for designing, selecting and/or optimizing small-molecule allosteric processing inhibitors that inhibit activation of proMMP9 and proMMP9 homologues. The present invention also relates to the use of small-molecule allosteric processing inhibitors for the treatment of diseases mediated by inappropriate matrix metalloproteinase (MMP) activity.

Methods of treatment using allosteric processing inhibitors for matrix metalloproteinases

A method of reducing or inhibiting kinase activity of C-KIT in a cell or a subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to C-KIT using a compound of the present invention: or a solvate, hydrate, tautomer or pharmaceutically acceptable salt thereof. The present invention is further directed to methods for treating conditions such as cancers and other cell proliferative disorders.

Method of inhibiting C-KIT kinase

The invention relates to arylamide and hetereoarylamide compounds of Formula I: wherein A, X, Rand W are set forth in the specification, as well as tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, colon cancer, stomach cancer, hairy cell leukemia and non-small lung carcinoma; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, Paget's disease, and other diseases in which bone resorption mediates morbidity including arthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of Formula I, are also provided.

Class of arylamide compounds useful as inhibitors of c-fms kinase

The invention is directed to compounds of Formula I: wherein A, X, Rand W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, colon cancer, stomach cancer, hairy cell leukemia and non-small lung carcinoma; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, Paget's disease, and other diseases in which bone resorption mediates morbidity including arthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of Formula I, are also provided.

Inhibitors of c-fms kinase

A method of inhibiting the production of cytokines, particularly inhibiting the production of tumor necrosis factor&agr;, interleukin-10, and macrophage inflammatory protein-1&agr; and the like, in a mammal, including a human, in need thereof which involves administering to such mammal an effective amount, preferably cytokine production inhibiting amount, of a polymethoxylated flavone.

Inhibition of cytokine production by polymethoxylated flavones

Growing community of inventors

Chester Springs, PA, United States of America

Carl L Manthey